Prof. Varda Shoshan-Barmatz's research forms the foundation of X-tosis technology, focusing on mitochondrial dysfunction and metabolic disorders. It centers on VDAC1, a key protein involved in energy regulation and apoptosis. Her work has paved the way for innovative therapeutic strategies targeting cancer, Alzheimer’s, cardiovascular disease, and type 2 diabetes, establishing X-tosis as a promising approach in these fields.

Erin has more than 25 years of experience in executive roles, including Chief Business Officer at Onconetix, Inc., and founder/CEO of The Aetos Group. She possesses extensive expertise in strategic planning, business development, and investor relations management.

My background: Yotam has over 15 years of experience in drug development, with expertise in Alzheimer's disease. He served as the CEO of ProteKt Therapeutics and Director of Research Collaboratoins at Minovia Therapeutics. He is experienced in preclinical and early-stage clinical development.

Ofer is experience in managing complex projects and more than 10 years in product management and entrepreneurship. Ensures operational efficiency and seamless process execution within the company to help bring a cure for patients.

Biotech executive with experience in start-ups, business development, and clinical trials. Former VP of Corporate Development at Athira Pharma and founder of S-Phase Ventures